Figure 2.
Figure 2. Characteristics of cytolytic activities of CD94-expressing cells against K562 leukemic cells. (A) Cytolytic activities of CD94-expressing cells against untreated K562 cells, IFN-γ–treated K562 cells, IFN-γ–treated K562 cells with HLA-B15 peptide (0.3 mM), with HLA-Cw3 peptide (0.3 mM), and with anti-NKG2A mAb (10 μg/mL) against autologous PHA blasts and allogeneic PHA blasts. (B) Cytolytic activities of CD94-expressing cells against untreated K562 cells, IFN-γ–treated K562 cells, and IFN-γ–treated K562 cells with anti–HLA class I mAbs (YTH862.2, G46-2.6, BRA-23/9, and W6/32, 20 μg/mL) and against autologous PHA blasts and allogeneic PHA blasts. (C) The cytolytic activities of CD94-expressing cells against K562 cells, against K562 cells with anti-NKG2C, anti-NKG2D, and anti-CD244 mAbs (20 μg/mL), against autologous PHA blasts and allogeneic PHA blasts. The data represented are the means ± SDs (effector-to-target ratio is 10:1).

Characteristics of cytolytic activities of CD94-expressing cells against K562 leukemic cells. (A) Cytolytic activities of CD94-expressing cells against untreated K562 cells, IFN-γ–treated K562 cells, IFN-γ–treated K562 cells with HLA-B15 peptide (0.3 mM), with HLA-Cw3 peptide (0.3 mM), and with anti-NKG2A mAb (10 μg/mL) against autologous PHA blasts and allogeneic PHA blasts. (B) Cytolytic activities of CD94-expressing cells against untreated K562 cells, IFN-γ–treated K562 cells, and IFN-γ–treated K562 cells with anti–HLA class I mAbs (YTH862.2, G46-2.6, BRA-23/9, and W6/32, 20 μg/mL) and against autologous PHA blasts and allogeneic PHA blasts. (C) The cytolytic activities of CD94-expressing cells against K562 cells, against K562 cells with anti-NKG2C, anti-NKG2D, and anti-CD244 mAbs (20 μg/mL), against autologous PHA blasts and allogeneic PHA blasts. The data represented are the means ± SDs (effector-to-target ratio is 10:1).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal